AQST

Aquestive Therapeutics, Inc. develops and commercializes differentiated pharmaceutical products primarily using its proprietary PharmFilm technology platform. Headquartered in Warren, New Jersey, the company focuses on delivering medicines through oral film formulations that dissolve on the tongue, addressing challenges related to medication adherence, safety, and efficacy. Aquestive's commercial portfolio includes Sympazan (clobazam oral film) for seizure treatment in Lennox-Gastaut syndrome patients, Suboxone (buprenorphine and naloxone sublingual film) for opioid dependence through a licensing agreement, and Exservan (riluzole oral film) for amyotrophic lateral sclerosis (ALS) treatment. The company also develops Libervant (diazepam buccal film) for acute repetitive seizures, which received FDA approval in 2021. Aquestive operates through both proprietary product development and partnerships with pharmaceutical companies seeking to reformulate existing drugs using its PharmFilm delivery system. The company's manufacturing capabilities include a facility in Portage, Indiana, producing oral soluble film products for both internal and partner programs. Recent developments include advancing its pipeline of complex molecules and expanding its partner-funded development programs. Aquestive generates revenue through product sales, licensing agreements, and manufacturing services. The company employs approximately 200 people and maintains strategic relationships with major pharmaceutical companies to leverage its drug delivery technology across multiple therapeutic areas, including neurology, psychiatry, and other specialty medicine categories.